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Abstract
Background Bronchoscopic lung volume reduction techniques are minor invasive treatment modalities for severely hyper-
inflated emphysema patients. The severity of static lung hyperinflation determines eligibility and success rate for these treat-
ments. However, it is not exactly known what parameter should be used to optimally reflect hyperinflation. Commonly used 
parameters are residual volume (RV) and the RV/Total lung capacity (TLC) ratio. Other parameters reflecting hyperinflation 
are Inspiratory Capacity/TLC and forced vital capacity.
Objectives To define which of these function parameters is the most optimal reflection of hyperinflationin in relation to 
patient-related outcomes.
Methods In a retrospective cohort study, data from measurements during baseline visits of eight studies were pooled. Pri-
mary outcomes were RV/TLC ratio and RV as percentage of predicted (RV%pred), both measured by bodyplethysmography, 
compared to the patient-related outcome variables: 6-min walk distance (6MWD), the St. George’s Respiratory Questionnaire 
(SGRQ), and the modified Medical Research Council (mMRC).
Results Two hundred seventy-four COPD patients (mean age 59 years; 66% female),  FEV1 0.74 ± 0.28 L, RV 4.94 ± 1.06 L, 
6MWD of 339 ± 95 m, were included in the analysis. Significant correlations (all p < 0.01) were found between RV%pred 
and 6MWD (r =  − 0.358), SGRQ (r = 0.184), and mMRC (r = 0.228). Also, there was a significant correlation between RV/
TLC ratio and 6MWD (r =  − 0.563), SGRQ (r = 0.289) and mMRC (r = 0.354). Linear regression analyses showed that RV/
TLC ratio was a better predictor of patient outcomes than RV%pred.
Conclusion This study demonstrates that both RV/TLC ratio and RV%pred are relevant indicators of hyperinflation in patients 
with severe emphysema in relation to patient-related outcomes. RV/TLC ratio is more strongly related to the patient-related 
outcomes than RV%pred.
Keywords Hyperinflation · Emphysema · Residual volume · Lung volume reduction · COPD
Introduction
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive and incurable disease. This is initially reflected by 
a reduced forced expiratory volume in 1 s  (FEV1) as well 
as a reduced  FEV1/forced vital capacity (FVC) ratio [1, 2]. 
Over time, this will lead to a further decrease in expiratory 
flow and increase in lung static hyperinflation [3]. Patients 
will experience limitations in rest increasing with exercise 
as there is an increased end-expiratory lung volume. During 
exercise, the time for the lungs to empty is reduced, lead-
ing to incomplete lung emptying, which results in dynamic 
hyperinflation. Both static and dynamic hyperinflation are 
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directly associated with patient-centered outcomes [4, 5]. 
The level of disability experienced among patients with 
COPD varies widely, but can be measured using commonly 
used tools such as the modified Medical Research Council 
(mMRC) dyspnea scale, the 6-min walk test (6MWT), and 
the St. George’s Respiratory Questionnaire (SGRQ) [6–9]. 
These outcomes can be improved by interventions that 
reduce static hyperinflation [3, 10] such as bronchodilators, 
breathing exercises, and surgical and bronchoscopic lung 
volume reduction (BLVR) techniques [11–13]. Especially 
for lung volume reduction modalities, the severity of static 
lung hyperinflation largely determines eligibility and success 
rate for these treatments [14, 15]. However, it is not exactly 
known what parameter should be used to optimally reflect 
hyperinflation. Therefore, the there is a need to find the best 
objective standards to identify patients who potentially ben-
efit most from BLVR remains.
Various lung function parameters can be used to meas-
ure hyperinflation. The most commonly used parameters to 
reflect static hyperinflation are the residual volume (RV) and 
the ratio of RV to total lung capacity (RV/TLC). Another 
lung function parameters reflecting hyperinflation is the ratio 
of the inspiratory capacity (IC) to TLC, and a low IC/TLC 
ratio (< 0.25) has been demonstrated to be prognostically 
unfavorable [16]. Furthermore, forced vital capacity (FVC) 
can be easily measured with spirometry and is negatively 
affected by hyperinflation [17]. The purpose of this study 
was to define which of these parameters is the most optimal 
reflection of lung hyperinflation in emphysema patients in 
relation to patient-related outcomes.
Methods
Patients and Study Design
This was a retrospective cohort study that included patients 
who were participants in eight different previous studies 
(performed between October 2006 and April 2016, see 
online Tables A1 and A2 for details) evaluating a BLVR 
treatment [18–25]. All study patients gave written informed 
consent and all studies were approved by the local ethics 
committee.
Pulmonary Function Testing
Pulmonary function was measured post bronchodilator 
(400 µg salbutamol) and according to ATS/ERS guide-
lines [26, 27]. The following variables were measured dur-
ing spirometry: inspiratory vital capacity (IVC), FVC, and 
 FEV1. Body plethysmography (Jaeger MasterScreen™ body 
plethysmograph (CareFusion, Germany)) was performed 
after the spirometry, and used to measure TLC, RV and 
functional residual capacity (FRC).
Patient‑Related Outcome Measurements
During the baseline visit the mMRC and SGRQ were 
obtained. The 6MWT was performed at baseline and in 
accordance with ATS guidelines, and percentages of pre-
dicted were calculated from normal values [6–9, 28].
Outcome Measures
The primary outcome measures of interest were the correla-
tion of RV/TLC ratio and RV as percentage of the predicted 
value (RV%pred) to the mMRC, SGRQ, and 6MWT. Other 
outcome measures were correlations of other potential meas-
urements of hyperinflation: FVC%pred, IC/TLC ratio to the 
mMRC, SGRQ, and 6MWT.
Statistical Analysis
Correlation coefficients were calculated to establish whether 
there was a correlation between pulmonary function vari-
ables and patient-related outcomes. When data were nor-
mally distributed, Pearson correlation was used. Spearman 
correlation was used when data were not normally distrib-
uted. Linear regression analysis was performed to evaluate 
the independent predictors of 6MWD and SGRQ and we 
included the primary outcome measures only. Variables with 
a univariate association with a p-value of < 0.20 were consid-
ered to be used in a linear regression model (method enter). 
The linear regression model was adjusted for age, gender, 
height, and weight. Highly correlating variables (correla-
tion coefficient > 0.70) were not included in the model, 
because of multicollinearity. RV/TLC ratio, RV%pred, and 
FVC%pred were divided in categories and then used in 
the linear regression analyses as follows: RV/TLC < 50%, 
50–55%, 55–58%, 58–62%, 62–65%, 65–70%, and > 70%; 
RV%pred < 175%, 175–200%, 200–225%, 225–250%, 
and > 250%; FVC%pred < 60%, 60–70%, 70–80%, 80–90%, 
90–100%, and > 100%. A p-value of < 0.05 was considered 
statistically significant. IBM SPSS Statistics version 23 
(IBM, NY, USA) was used for all analyses.
Results
A total of 275 patients with severe COPD were included 
in this study, with one patient being excluded from further 
analysis because of missing body plethysmograph measure-
ments. Thus, a total of 274 were used for the final analyses 
(See Table 1 for patient characteristics).
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Significant correlations were found between both RV/
TLC ratio and 6MWD (r =  − 0.563, p < 0.001) and between 
RV%pred and 6MWD (r =  − 0.358, p < 0.001). We found 
lower, but still statistically significant correlations of RV/
TLC ratio and RV%pred with SGRQ (Fig. 1a–f) (See Table 2 
for all correlations).
Linear regression analyses showed that RV/TLC ratio, 
RV%pred, and FVC%pred are independent predictors of 
6MWD (online supplement, Tables 3A–C). The model 
using RV/TLC ratio explained most of the variation in 
6MWD (R2 = 0.476). When RV/TLC ratio increases by 
one percent, a patient walks approximately 4.8 m fewer 
(b =  − 4.812). Linear regression analyses of SGRQ 
showed that the primary outcome measures (RV/TLC 
ratio, RV%pred) and FVC%pred are not independent pre-
dictors of SGRQ (online supplement, Tables A3A–C). We 
also performed linear regression analyses with the primary 
outcome measures divided into categories. We found sig-
nificant differences between the RV/TLC ratio categories. 
This model explained 47.3% of the variation in 6MWD 
(online supplement, Table  A4A). Using this model, a 
hypothetical patient with a RV/TLC ratio of > 70% walked 
approximately 116 m less during a 6MWT compared to 
patients with a RV/TLC ratio < 50%. The model with 
RV%pred can be used to explain 41.4% of the variation in 
6MWD outcome. When using RV%pred > 250% as refer-
ence value, all other categories were significantly different 
compared to this reference category. The model including 
FVC%pred (Table A4C) explained 46.7% of the variation 
in 6MWD outcome. In addition, linear regression analyses 
of SGRQ showed no significant differences between sev-
eral categories of RV/TLC ratio, RV%pred, and FVC%pred 
(online supplement, Tables A5A–C).
Table 1  Patient characteristics 
(N = 274)
Results are presented as mean ± standard deviation. Other parameters are presented as numbers
FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, TLC total lung capacity, VC vital capac-




 Age (years) 59 ± 8
 Body Mass Index (kg/m2) 23.7 ± 3.6
 Pack years (1/year) 37 ± 17
Pulmonary function
 FVC (Liter) 2.57 ± 0.83
 FVC (% of predicted value) 76.07 ± 17.45
 FEV1 (Liter) 0.74 ± 0.28
 FEV1 (% of predicted value) 26.99 ± 8.59
 FEV1/FVC (%) 29.39 ± 6.93
 TLC (Liter) 7.84 ± 1.41
 Predicted TLC (Liter) 5.77 ± 1.06
 VC (Liter) 2.88 ± 0.87
 FRC (Liter) 6.08 ± 1.23
 RV (Liter) 4.94 ± 1.06
 IC (Liter) 1.76 ± 0.59
 Raw (kPa/Liter/second) (N = 245) 0.74 ± 0.28
 SGaw, 1/(kPa*second) (N = 213) 0.26 ± 0.12
 Ratio of RV to TLC (%) 63.12 ± 8.06
 Ratio of RV to TLC predicted (%) 86.62 ± 16.05
 Ratio of IC to TLC (%) 22.51 ± 6.41
 Ratio of FVC to VC (%) 88.16 ± 8.23
 Ratio of FRC to TLC (%) 77.49 ± 6.41
Patient related outcomes
 St. George’s respiratory questionnaire, total score (N = 269) 61.2 ± 12.3
 6-min walk distance (N = 273), meter 339 ± 95
 % of predicted value 61 ± 17




The results of this study show that RV/TLC ratio and 
RV%pred both provide relevant information about the 
impact of hyperinflation on the patients quality of life and 
exercise tolerance, with RV/TLC ratio being the best predic-
tor of the variation in outcomes.
Interestingly, the correlation of RV/TLC to patient-related 
outcomes is stronger than the correlation between RV%pred 
and patient-related outcomes. A possible explanation is that 
RV/TLC is calculated by dividing the actual measured RV 
in liters by the patients’ own actual measured TLC in liters, 
thus not being limited by predicted values based on length, 
age, and gender. In other words, RV%pred is a general 
parameter, with potential bias, making it a little less suit-
able for accurate individual measurement of hyperinflation. 
Our results are in line with an earlier study in surgical lung 
volume reduction patients, which reported a strong correla-
tion between RV/TLC ratio and the reduction in  FEV1 [29] 
(Table 3).
Fig. 1  a scatterplot of 6-min walk test (6MWT) and residual volume/
total lung capacity ratio (RV/TLC); b scatterplot of 6MWT and RV % 
of predicted; c scatterplot of the Saint George’s Respiratory Question-
naire (SGRQ) and RV/TLC ratio; d scatterplot of SGRQ and RV % of 
predicted; e boxplot of the modified medical Research Counsel dysp-
nea scale (mMRC) and RV/TLC ratio; f boxplot of mMRC and RV % 
of predicted. *Indicates p < 0.05
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The results of this study showed that the primary out-
come variables (RV/TLC ratio, RV%pred) and FVC%pred 
correlated best with 6MWD and SGRQ. Many factors are 
known to contribute to the 6MWD in this patient group. 
Previous studies showed that 6MWD correlated to multiple 
pulmonary function variables such as RV/TLC ratio,  FEV1, 
 FEV1 as percentage of predicted value, FVC, and  FEV1/
FVC ratio, but also age, weight, gender, and height, and 
even SGRQ and mMRC explain a great variety in 6MWD 
[30, 31]. Even a learning curve could also be an influencing 
factor: the more often someone performs the test, the better 
this person understands in which manner the best result can 
be achieved [28, 32]. Contrary to the 6MWD, there are just 
minimal correlations between the pulmonary function test 
values and SGRQ. Furthermore, the independent predictors 
that were significant for 6MWD were not significant for the 
SGRQ. This is somewhat surprising, since the previous stud-
ies indicate a quite fair clinical significance of the SGRQ to 
other clinical outcomes [7, 8]. A possible explanation might 
be that this questionnaire is a more subjective measurement 
than the 6MWT. Furthermore, it may be that patients with 
the most advanced COPD (such as our now evaluated very 
severe emphysema patients) were not included in the initial 
validation studies of the SGRQ. This is also reflected by 
the fact that we recently showed that the minimal clinical 
important difference for the SGRQ total score for this patient 
Table 2  Correlations overview
IVC inspiratory vital capacity, FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, TLC total 
lung capacity, RV residual volume, FRC forced residual capacity, Raw airway resistance, SGaw 1/airway 
resistance, IC inspiratory capacity, mMRC modified medical research council scale, SGRQ St. George’s 
Respiratory Questionnaire, 6MWD 6-min walk distance
Significant values (p < 0.05) were depicted in bold. * 0.05 ≥ p ≤ 0.20
Variable mMRC p-value SGRQ p-value 6MWD p-value
Pack years (years) 0.008 0.893 0.051 0.404  − 0.008 0.897
Age (years) 0.113* 0.067* 0.079* 0.198* − 0.141 0.019
Height (centimeter)  − 0.103* 0.093*  − 0.090* 0.142* 0.195 0.001
Weight (kg)  − 0.020 0.742  − 0.030 0.623 0.047 0.436
Body Mass Index (kg/m2) 0.050 0.419 0.026 0.669  − 0.078* 0.200*
IVC (L)  0.307  < 0.001 − 0.246  < 0.001 0.508  < 0.001
IVC (% of predicted value) − 0.271  < 0.001  − 0.227  < 0.001 0.458  < 0.001
VC (L) − 0.302  < 0.001 − 0.257  < 0.001 0.464  < 0.001
FVC (L)  − 0.294  < 0.001 − 0.244  < 0.001 0.484  < 0.001
FVC (% of predicted value)  − 0.250  < 0.001  − 0.218  < 0.001 0.416  < 0.001
FEV1 (L)  − 0.328  < 0.001 − 0.199 0.001 0.542  < 0.001
FEV1 (% of predicted value) − 0.272  < 0.001 − 0.141 0.021 0.466  < 0.001
TLC (L)  − 0.059 0.335  − 0.048 0.434 0.116* 0.055*
TLC (% of predicted value) 0.098* 0.110* 0.058 0.346 − 0.127 0.037
RV (L) 0.169 0.006 0.134 0.028 − 0.254  < 0.001
RV (% of predicted value) 0.228  < 0.001 0.184 0.002 − 0.358  < 0.001
FRC (L) 0.071 0.248 0.050 0.414 − 0.129 0.033
FRC (% of predicted value) 0.206 0.001 0.145 0.017 − 0.335  < 0.001
Raw (kPa/Liter/second) 0.329  < 0.001 0.317  < 0.001 − 0.489  < 0.001
Raw (% of predicted value) 0.290  < 0.001 0.301  < 0.001 − 0.494  < 0.001
SGaw, 1/(kPa*second) − 0.273  < 0.001 − 0.236 0.001 0.512  < 0.001
SGaw (% of predicted value) − 0.289  < 0.001 − 0.260  < 0.001 0.553  < 0.001
IC (L)  − 0.302  < 0.001 − 0.227  < 0.001 0.529  < 0.001
RV/TLC (%) 0.354  < 0.001 0.289  < 0.001  0.563  < 0.001
RV/TLCpredicted (%) 0.298  < 0.001 0.228  < 0.001  0.452  < 0.001
Ratio of FVC to VC (%)  − 0.010 0.877  − 0.043 0.486 0.005 0.939
Ratio of IC to TLC (%) − 0.307  < 0.001 − 0.227  < 0.001 0.550  < 0.001
Ratio of FRC to TLC (%) 0.305  < 0.001 0.244  < 0.001  − 0.547  < 0.001
Ratio of  FEV1 to FVC (%) − 0.162 0.008  − 0.004 0.953 0.245  < 0.001
SGRQ (points) 0.518  < 0.001 – – − 0.368  < 0.001
6MWD (meter) − 0.512  < 0.001 − 0.368  < 0.001 – –
mMRC (points) – – 0.518  < 0.001 − 0.512  < 0.001
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group is a change of 7 points 6 months after intervention, 
whereas the validation literature showed a difference of only 
4 points in a patient population with milder COPD [8, 33].
Looking at the mMRC, it might be concluded that this 
parameter was not as useful as we expected. Considering 
this is a categorical variable with a zero to four scale, it is 
perhaps less sensitive to detect feelings of breathlessness 
related to the level of hyperinflation. Another explanation 
for a low sensitivity might be that the mMRC is not a 
composite measure, but only measures the general dysp-
nea sensation. The results of this study are in line with an 
earlier study that demonstrated a discrepancy when com-
paring several scores from mMRC with COPD assessment 
test (CAT; health status) [34]. On the other hand, it can be 
noticed that in every linear regression model of the predic-
tors of 6MWD and SGRQ, mMRC is a sensitive predic-
tor. Therefore, the exact role of mMRC when determining 
hyperinflation remains unclear.
Next to RV/TLC ratio, FVC is also of great importance 
to display the health status after a procedure. A relative 
simple explanation can be that after lung volume reduc-
tion, the RV/TLC ratio improves and so does VC, and 
thus FVC. Previous research showed improved FVC is an 
important predictor of an improved  FEV1 [35]. Also in 
our data, a high correlation was found between FVC and 
6MWD (r = 0.484, p < 0.001), as well as significant, but 
slightly weaker correlations between FVC and SGRQ or 
mMRC. So FVC might be a relevant variable when try-
ing to select patients who benefit most from BLVR. The 
potential advantage of using FVC as a “screening” tool is 
the fact that it can be derived from a simple spirometry 
(flow/volume measurement), making it a cheap and easy 
to use tool.
The FVC/VC ratio does not correlate significantly with 
any patient-related outcome variable (Table 2). This can be 
explained by the fact that both parameters are strongly asso-
ciated, and thus leverage each other. The impact of  FEV1/
FVC ratio is not strongly correlated with patient-related out-
comes as well. Generally, this ratio is used to indicate the 
amount of airflow limitation [36]. Also, this study showed 
a weak but significant correlation between this ratio and 
6MWD (r =  − 0.245, p < 0.001). Furthermore, the correla-
tion between  FEV1/FVC ratio and SGRQ is not significant 
at all (r =  − 0.004, p = 0.953). A conclusion could be that 
 FEV1/FVC ratio does not correspond to the clinical magni-
tude of hyperinflation and is therefore less suitable for the 
goal of this study.
Another variable we looked at was IC/TLC ratio. In our 
study population both functional residual capacity and TLC 
are increased. As a result, IC is decreased and a situation 
arises which is referred to as hyperinflation. IC/TLC ratio 
correlates significantly with all patient outcome variables, 
yet comparable with RV/TLC ratio. Therefore, it might be 
useful to keep this ratio in mind when trying to select the 
best patients for BLVR. The small downside of using IC/
TLC, is that a separate IC maneuver needs to be performed 
to capture this data, while with measuring and calculating 
TLC, RV is readily available.
The goal of this study was to determine which of our 
selected parameters is the best reflection of hyperinflation in 
relation to patient-related outcomes. Much research has been 
conducted to discover the physiological concepts behind 
lung volume reduction, with patients having static hyper-
inflation, and reducing this by many different interventions 
being the main driver of response [37]. This study is one of 
the first to specify the best measure of static hyperinflation 
in this patient population
Table 3  Linear model of predictors of 6MWD (meter)
(a) R2 =  0.476; (b) R2 = 0.413; (c)R2 = 0.467
RV residual volume, TLC total lung capacity, RV_TLC_ratio ratio of 
RV to TLC, RV_perc_pred residual volume, percentage of predicted 
value, FVC_perc_pred forced vital capacity, percentage of predicted 
value, FEV1 forced expiratory volume in 1 s, FVC forced vital capac-
ity, 6MWD 6-min walk distance, mMRC modified Medical Research 
Council dyspnea scale, SGRQ St. George’s Respiratory Questionnaire
Significant values (p < 0.05) were depicted in bold
Variable b SE B β p-value
A
 RV/TLC  − 4.812 0.621  − 0.404  < 0.001
 Ratio of  FEV1 to FVC 2.584 0.666 0.187  < 0.001
 Age  − 0.509 0.602  − 0.043 0.398
 Gender 1.822 13.913 0.009 0.896
 Height 1.925 0.792 0.174 0.016
 Weight  − 1.219 0.424  − 0.159 0.004
 mMRC  − 36.584 7.545  − 0.272  < 0.001
 SGRQ  − 0.783 0.420  − 0.101 0.063
B
 RV_perc_pred  − 0.634 0.124  − 0.287  < 0.001
 FEV1/ FVC 2.036 0.736 0.147 0.006
 Age  − 2.242 0.638  − 0.189 0.001
 Gender  − 4.087 14.715  − 0.020 0.781
 Height 2.719 0.851 0.246 0.002
 Weight  − 1.139 0.450  − 0.148 0.012
 mMRC  − 42.776 7.898  − 0.318  < 0.001
 SGRQ  − 0.925 0.445  − 0.119 0.038
C
 FVC_perc_pred 1.946 0.262 0.358  < 0.001
 FEV1/ FVC 4.012 0.677 0.290  < 0.001
 Age  − 1.913 0.595  − 0.161 0.001
 Gender  − 22.788 13.836  − 0.113 0.101
 Height 2.124 0.799 0.192 0.008
 Weight  − 0.996 0.425  − 0.130 0.020
 mMRC  − 35.882 7.636  − 0.266  < 0.001
 SGRQ  − 1.009 0.420  − 0.130 0.017
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In conclusion, we showed that both RV/TLC ratio and 
RV%pred are relevant indicators of hyperinflation in relation 
to patient-related outcomes in patients with severe emphy-
sema, with the RV/TLC ratio being the best predictor of 
the variation in baseline 6MWD. Further research is neces-
sary to even more accurately determine other measures of 
hyperinflation that correlate with limitations experienced by 
patients.
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